BX471 (ZK811752, BAY 865047, SH T 04268H) is a potent nonpeptide CC chemokine receptor-1 (CCR1) antagonist with Ki values of 1 nM and 5.5 nM in both MIP-1α and MCP-3 binding to CCR1-transfected HEK293 cells, respectively.
research use only
Cat.No.S7604
| Related Targets | CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas |
|---|---|
| Other CCR Inhibitors | Cenicriviroc ZK756326 2HCl INCB3344 Vicriviroc Malate SB-297006 R243 Adaptavir (DAPTA) RS102895 BMS-813160 AZD2098 |
|
In vitro |
DMSO
: 87 mg/mL
(200.05 mM)
Ethanol : 22 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 434.89 | Formula | C21H24ClFN4O3 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 217645-70-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | ZK811752, BAY 865047, SH T 04268H | Smiles | CC1CN(CCN1C(=O)COC2=C(NC(N)=O)C=C(Cl)C=C2)CC3=CC=C(F)C=C3 | ||
| Targets/IC50/Ki |
CCR1
(in MIP-1α binding assay) 1 nM(ki)
CCR1
(in MCP-3 binding assay) 5.5 nM(ki)
|
|---|---|
| In vitro |
By displacing the ligand binding to CC chemokine receptor-1 (CCR1), BX 471, a potent antagonist, can inhibit the effects medicated by CCR1. In addition, BX-471 exhibits anti-allergic effect by increasing Treg cell population.<sup><a class="sref" href="#s_ref">[1]</a></sup><sup><a class="sref" href="#s_ref">[2]</a></sup> |
| In vivo |
For fasted dogs, the half-life for BX 471 was approximately 3 h, with an oral bioavailability of approximately 60%. In rats of EAE model, CCR1 antagonist, BX 471, dose-dependently decreased the severity of the disease.<sup><a class="sref" href="#s_ref">[1]</a></sup> |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.